Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Airway management, procedural data, and in-hospital mortality records of patients undergoing surgery for mucormycosis associated with coronavirus disease (COVID-19)

Prashant Sirohiya, Saurabh Viga, Tanmay Mathura, Jitendra Kumar Meenab, Smriti Pandac, Gitartha Goswamia, Raghav Guptaa, Abhilash konkimallac, Dheeraj Kondamudic, Nishkarsh Guptaa, Brajesh Kumar Ratrea, Ram Singha, Balbir Kumar, Anuja Pandit, Kapil Sikka, Alok Thakarc, Sushma Bhatnagara

a Department of Onco-anaesthesia and Palliative Medicine, All India Institute of Medical Sciences, New Delhi, India
b Department of Preventive Oncology, All India Institute of Medical Sciences, New Delhi, India
c Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences, New Delhi, India

ARTICLE INFO
Article History:
Received 27 September 2021
Revised 4 May 2022
Accepted 1 July 2022
Available online 2 July 2022

Keywords:
Airway
COVID-19
Mucormycosis
Coronavirus disease
Intubation difficulty scale
Mortality

ABSTRACT
Purpose: Although unexpected airway difficulties are reported in patients with mucormycosis, the literature on airway management in patients with mucormycosis associated with Coronavirus disease is sparse.
Methods: In this retrospective case record review of 57 patients who underwent surgery for mucormycosis associated with coronavirus disease, we aimed to evaluate the demographics, airway management, procedural data, and in-hospital mortality records.
Results: Forty-one (71.9%) patients had a diagnosis of sino-nasal mucormycosis, fourteen (24.6%) patients had a diagnosis of rhino-orbital mucormycosis, and 2 (3.5%) patients had a diagnosis of palatal mucormycosis. A total of 44 (77.2%) patients had co-morbidities. The most common co-morbidities were diabetes mellitus in 42 (73.6%) patients, followed by hypertension in 21 (36.8%) patients, and acute kidney injury in 14 (28.1%) patients. We used the intubation difficulty scale score to assess intubating conditions. Intubation was easy to slightly difficult in 53 (92.9%) patients. In our study, mortality occurred in 7 (12.3%) patients. The median (range) mortality time was 60 (27−74) days. The median (range) time to hospital discharge was 53.5 (10−85) days. The median [interquartile range] age of discharged versus expired patients was 47.5 [41,57.5] versus 64 [47,70] years (P=0.04), and median (interquartile range) D-dimer levels in discharged versus expired patients was 364 [213, 638] versus 2448 [408,3301] ng/mL (P=0.03).
Conclusion: In patients undergoing surgery for mucormycosis associated with the coronavirus disease, airway management was easy to slightly difficult in most patients. Perioperative complications can be minimized by taking timely and precautionary measures.

© 2022 SFMM. Published by Elsevier Masson SAS. All rights reserved.

Introduction
Mucormycosis is an acute-onset, aggressive, and rapidly progressive angioinvasive infection caused by saprophytic fungi of the order Mucorales. The most common underlying risk factor associated with mucormycosis is uncontrolled diabetes mellitus. Hematopoietic stem cell and solid organ transplants, corticosteroid therapy, neutropenia, or drug-induced immunosuppression are other identifiable risk factors [1,2].

There was a sudden increase in cases of mucormycosis in the second wave of Coronavirus disease (COVID-19) in India [3,4]. The management plan of these cases included surgical debridement, systemic antifungal therapy, sugar control, and management of systemic adverse effects related to the antifungal therapy [5]. Diabetes mellitus has been recognized as the most common coexisting concomitant disease. Attention must be given to control blood glucose [6]. In addition, airway management in these patients may be difficult due to the aggressive nature of the disease. The oropharyngeal region may be involved by fungi and edema in the supraglottic region may cause difficult endotracheal intubation and difficult ventilation [7−9]. These patients are receiving injections of amphotericin B which may have significant adverse effects such as nephrotoxicity, hypokalemia, hypomagnesemia, fever, tremor, dyspnea, and hypotension [10]. Apart from this, COVID-19 itself has harmful effects on various organs of the body. Many of these patients require surgical debridement of

Please note that the above text is a natural representation of the document as if you were reading it naturally. The text has been formatted to match the style and structure of the original document as closely as possible, ensuring that all original content and information are accurately represented.
the involved tissues and anesthesiologists are involved in the multi-disciplinary perioperative management of mucormycosis associated with COVID-19 [9].

The mortality rate for mucormycosis associated with COVID-19 is less known, but a study on 929 patients with mucormycosis found a mortality rate of 54%. This includes mucormycosis infections such as sinus, pulmonary, cutaneous, cerebral, gastrointestinal, generalized disseminated, kidney, and others [11]. In sinus infections, there is a risk of involvement of vital structures such as the brain and eye, so surgical debridement should be planned on an urgent basis as a delay can worsen the prognosis. There may be less time to optimize patient comorbidities, making perioperative management challenging. Since all patients in our study are positive for COVID-19, problems caused by wearing personal protective equipment, limited staffing, and supplies are additional difficulties in managing these patients [12].

Although unexpected airway difficulties are reported in patients with mucormycosis, the literature on airway assessment and management in patients with mucormycosis associated with COVID-19 is sparse. In this study, we aimed to evaluate demographics, airway assessment and management, procedural data, and in-hospital mortality records in patients undergoing surgery for mucormycosis associated with COVID-19.

Methods

Study design

A retrospective review of the medical records of patients who underwent surgery for mucormycosis associated with COVID-19 at the National Cancer Institute (Jhajjar) between 6 May 2021 and 15 June 2021 was performed [13].

Study setting and population

The study included 57 COVID-19 positive patients who underwent surgery for mucormycosis under general anesthesia. The study was approved by the Institute Ethics Committee (IEC-450/02.07.2021) of the All India Institute of Medical Sciences, New Delhi.

Study objectives

The primary objective was to describe airway assessment and management and the secondary objective of the study was to describe demographics, procedural data, and in-hospital mortality records.

Study protocol

Preoperative data included demographic characteristics, disease type, patient comorbidities, smoking and alcohol status, laboratory investigations, vital parameters, and airway assessment. The airway was assessed under the following headings: mouth opening, presence of loose teeth, dentures or bucktooth, whether the patient was edentulous, Mallampatti scoring, neck movements, thyromental distance, presence of short neck, presence of receding chin, and postsurgical changes [14,15]. All the surgeries were performed under general anesthesia. All anesthesiologists involved in the procedure had at least 3 years of clinical experience. As a protocol and according to recommendations, if mouth opening was adequate, we used a conventional C-MAC video laryngoscope for endotracheal intubation [9,16,17]. We calculated the Intubation difficulty score (IDS) to assess intubating conditions [18–20]. This includes the following parameters: number of intubation attempts, number of operators, number of alternative techniques, Cormack-Lehane grade, whether lifting pressure is necessary, whether or not laryngeal pressure is applied, and vocal cord mobility. IDS value = 0 represents easy intubation, a score of >0 and <5 represents slightly difficult intubation, and a score ≥5 represents moderate to major difficult intubation. The time required for intubation and the percentage of glottic opening (POGO) were also noted [21]. Data related to the procedure were also recorded in terms of nasogastric tube insertion, invasive monitoring, central venous catheter insertion, blood loss, urine output, etc.

The duration of anesthesia was defined as the time between induction of anesthesia and transfer of the patient to the post-anesthesia care unit (PACU) or ICU. Patients who required postoperative mechanical ventilation or who had undergone extensive surgery were transferred directly from the operation theater to the ICU. Patient data regarding length of hospital stay and mortality were obtained from hospital records. Duration of hospital stay was defined as the number of days between the date of hospitalization to the date of discharge/death. If the patient’s condition was clinically stable and they completed the course of liposomal amphotericin B, we discharged them on posaconazole tablets, and asked them to follow-up after 3 months at our main hospital i.e., All India Institute of Medical Sciences, New Delhi.

Statistical analysis

The study design was descriptive in nature and followed a retrospective record review design, therefore a priori calculation of sample size wasn’t performed. Instead we included the records of all patients (n = 57) who were admitted to our center and underwent surgery for mucormycosis related to COVID-19. The study period corresponds to the peak phase of 2nd wave of COVID-19 pandemic in the country with high mucormycosis admissions, so a non probabilistic, convenience sample selection of the patient records was performed. Data related to the variables selected in the study were extracted from the records and entered into MS Excel software version 16.0 (Microsoft Inc.) for summative analysis. Data were summarized using the median with the interquartile range [25th, 75th] or median (range) for continuous variables and numbers and proportions (%) for categorical variables. Statistical review of the data was performed using IBM SPSS version 24 (SPSS Inc., Chicago IL, USA). A P-value of less than 0.05 was considered statistically significant.

Results

The demographic and clinical characteristics of the patients are presented in Table 1. The 57 patients consisted mostly of men 35 (61.4%) with a median age of 49 (26.78) years. The median body weight and height were 64 (46.82) kg and 1.67 (1.45,1.81) meters. Most patients had American Society of Anesthesiologists (ASA) scores II (40.4%) and III (40.4%) [22]. Forty-one (71.9%) patients had sinonasal mucormycosis, fourteen (24.6%) had rhino-orbital mucormycosis (out of which 2 patients had a cerebral extension), and 2 patients (3.5%) was diagnosed with palatal mucormycosis. The diagnosis of mucormycosis in our study was based on clinical suspicion, potassium hydroxide (KOH) stain examination, culture, and histopathology. Total 44 (77.2%) patients had co-morbidities. The most common co-morbidity was Diabetes Mellitus 42 (73.6%), followed by hypertension 21 (36.8%) and Acute kidney injury 14 (28.1%). A total of 22 (52.4%) out of 42 diabetic patients were recently diagnosed with diabetes mellitus at presentation.

The severity of COVID-19 in patients was defined as per the guidelines of the All India Institute of Medical Sciences, the Indian Council of Medical Research, and Ministry of Health and Family Welfare [23]. The severity of COVID-19 disease, the treatment history of COVID-19 before the detection of mucormycosis, and days without oxygen therapy before surgery are mentioned in Table 1. All the patients on oxygen therapy were weaned off from it before their surgery.

Airway assessment and management, and procedural data parameters are presented in Table 2. In all 57 patients, mask ventilation was
Demographic and clinical characteristics of included cases in the study.

Table 1

| Variables                      | Frequency (%) | Median [IQR] |
|--------------------------------|---------------|--------------|
| 1. Age (Years)                 | 49 [41.5, 59.5] |              |
| 2. Weight (Kilograms)          | 64 [58.7]     |              |
| 3. Height (meters)             | 1.67 [1.58, 1.71] |              |
| 4. Sex:                        |               |              |
| Male                           | 35 (61.4)     |              |
| Female                         | 22 (38.6)     |              |
| 5. Diagnosis:                  |               |              |
| Sino-nasal                     | 41 (71.9)     |              |
| Rhino-orbital                  | 14 (24.6)     |              |
| Palatal                        | 2 (3.5)       |              |
| 6. Symptoms                    |               |              |
| Facial Pain                    | 43 (75.4)     |              |
| Headache                       | 38 (66.7)     |              |
| Swelling on face               | 28 (49.1)     |              |
| Diminished vision              | 10 (17.5)     |              |
| Ptosis                         | 6 (10.5)      |              |
| Deviation of angle of mouth    | 4 (7.1)       |              |
| Nasal discharge                | 12 (21.1)     |              |
| Tooth pain                     | 26 (45.6)     |              |
| Eye pain                       | 18 (31.6)     |              |
| Eye swelling                   | 17 (29.8)     |              |
| 7. Onset of Symptoms of mucormycosis (Days) | 6 [5.8] |              |
| 8. Days from COVID-19 infection to detection of mucormycosis | 10 [7, 17] |              |
| 9. Treatment history of COVID-19 in patients at presentation |               |              |
| No treatment                   | 6 (10.5%)     |              |
| Supportive treatment only (Antipyretics, Antiallergics, Antitussives, Bronchodilators) | 17 (29.8%) |              |
| Supportive treatment + intravenous/oral steroids | 20 (35.1%) |              |
| Oxygen therapy + Supportive treatment + intravenous/oral steroids + Anticoagulants | 14 (24.6%) |              |
| 10. Severity defined as per AIIMS, ICMR & MOHFW COVID-19 severity protocol) | Mild: 41 (71.9%), Moderate: 14 (24.6%), Severe: 2 (3.5%) |              |
| 11. Fungus Isolated            |               |              |
| KOH Stain                      |               |              |
| - Aseptate Hyphae              | 45 (78.9)     |              |
| - Septate + Aseptate Hyphae    | 3 (5.3)       |              |
| - Negative                     | 9 (15.8)      |              |
| Culture                        |               |              |
| - Rhizopus Species             | 31 (54.3)     |              |
| - Mucor Species                | 2 (3.5)       |              |
| - Rhizopus Species + Fusarium Species | 1 (1.8) |              |
| - Mucor Species+Aspergillus Species | 1 (1.8) |              |
| - Lichthermia Species          | 1 (1.8)       |              |
| - Negative                     | 21 (36.8)     |              |
| Histopathology                 |               |              |
| - Macormycosis                 | 40 (70.1)     |              |
| - Mucormycosis+Candidiasis     | 2 (3.5)       |              |
| - Mucormycosis+Aspergillus     | 3 (5.3)       |              |
| - Inflammatory mucosa          | 3 (5.3)       |              |
| - Reports Inconclusive/Not available | 9 (15.8) |              |
| 12. Days off oxygen before surgery (14 patients) | 7 [4.3, 17.8] |              |
| 13. Days from detection of mucormycosis to surgery (days) | 14 [12, 20] |              |
| 14. Duration of Pharmacological treatment before surgery (days) | 7 [5, 8] |              |
| 15. Clinical Outcome           |               |              |
| Discharged                     | 50 (87.7)     |              |
| Expired                        | 7 (12.3)      |              |
| 16. ASA Grade                  |               |              |
| 1                              | 11 (19.3)     |              |
| 2                              | 23 (40.4)     |              |
| 3                              | 23 (40.4)     |              |
| 17. Comorbidty                 |               |              |
| Diabetes                       | 42 (73.7)     |              |
| Hypertension                   | 21 (36.8)     |              |
| Acute Kidney Injury            | 14 (28.1)     |              |
| Chronic Kidney Disease         | 2 (3.8)       |              |

Table 1 (Continued)

| Variables                      | Frequency (%) | Median [IQR] |
|--------------------------------|---------------|--------------|
| 18. Pre-operative HbA1c values (%) | 9.1 [6.1, 10.9] |              |
| 19. Smoking Status*             | 10 [17.5]     |              |
| 20. Alcohol intake Status*      | 10 [17.5]     |              |
| 21. Pre-operative Pulse Rate (per minute) | 89 [79.5, 100.5] |              |
| 22. Pre-operative Systolic Blood Pressure | 125 [117.5, 136.5] |              |
| 23. Pre-operative Diastolic Blood Pressure | 75 [66.5, 84.5] |              |
| 24. Pre-operative Respiratory rate (breaths per minute) | 22 [20, 24] |              |

*Items are mutually non-exclusive.

Without difficulty. Fifty-six (98.3%) patients underwent oral endotracheal intubation using a conventional C-MAC laryngoscope. One patient who had rhino orbital mucormycosis has restricted mouth opening (<1 finger), for which we performed nasotracheal intubation using a fiberoptic bronchoscope. The first pass intubation success rate was 92.9%. We calculated the intubation difficulty score to assess intubating conditions and we found a score of 0 (Easy) in 11 patients, a score of 0 to <5 (slightly difficulty) in 42 patients, and a score ≥5

Table 2

| Variable                      | Frequency (%) |
|-------------------------------|---------------|
| 1. Mouth opening              |               |
| >3 Fingers                    | 49 (85.9)     |
| 2.5–3 Fingers                 | 3 (5.3)       |
| 2–2.5 Fingers                 | 4 (7.0)       |
| <1 Fingers                    | 1 (1.8)       |
| 2. Loose tooth                | 5 (8.8)       |
| 3. Artificial tooth           | 3 (5.3)       |
| 4. Edentulous                 | 2 (3.5)       |
| 5. Buck tooth                 | 2 (3.5)       |
| 6. Mallampatti Score          |               |
| 1                             | 3 (5.3)       |
| 2                             | 44 (77.2)     |
| 3                             | 8 (14.0)      |
| 4                             | 2 (3.5)       |
| 7. Neck Movements             | 56 (98.2)     |
| 8. TMD (adequate)             | 46 (80.7)     |
| 9. Short neck                 | 7 (12.3)      |
| 10. Reeding chin              | 2 (3.5)       |
| 11. Post-surgical changes     | 0 (0)         |
| 12. No. of attempts           |               |
| 1                             | 53 (92.9)     |
| 2                             | 4 (7.0)       |
| 13. No. of operators          |               |
| 1                             | 56 (98.2)     |
| 2                             | 1 (1.8)       |
| 14. Cormack Lehane grade      |               |
| 1                             | 24 (42.9)     |
| 2                             | 28 (50.0)     |
| 3                             | 4 (7.0)       |
| 15. Lifting force required    |               |
| Normal                        | 24 (42.9)     |
| Increased                     | 32 (57.1)     |
| 16. Vocal cord mobility       |               |
| Abduction                     | 57 (100)      |
| 17. External laryngeal maneuver | 21 (36.8)   |
| 18. Esophageal intubation      | 0 (0)         |
| 19. Intubation Stylet used    | 2 (3.6)       |
| 20. Intubation difficulty score (n = 56) |              |
| 0                             | 11 (19.6)     |
| 1                             | 13 (23.2)     |
| 2                             | 17 (30.4)     |
| 3                             | 11 (19.6)     |
| 4                             | 1 (1.8)       |
| 5                             | 3 (5.4)       |
| 21. Shifted to ICU (Intubated) | 16 (28.1)     |
| (continued)                   |               |
The causes of death were identified as suspected pulmonary embolism with septic shock in 1 patient, cardiogenic shock in 1 patient, septic shock in 2 patients, septic shock with severe acute respiratory distress syndrome (ARDS) in 1 patient, middle cerebral artery infarction with septic shock and severe ARDS in 1 patient, and septic shock with acute kidney injury in 1 patient. According to the initial severity of COVID-19, 4 patients with mild disease, 2 patients with moderate disease, and 1 patient with severe disease died during their hospital stay. The median (range) time to hospital discharge was 53.5 (10–85) days. We did a comparative analysis between discharged patients and expired patients. The median (interquartile range) age of discharged versus expired patients was 47.5 [41,57.5] versus 64 [47,70] years (P = 0.04), and median (interquartile range) v-dimer levels in discharged versus expired patients was 364 [213,638] versus 2448 [408,3301] ng/mL (P = 0.03).

Discussion

Surgical debridement of mucormycosis is an invasive procedure and airway management of patients can be challenging. Involvement of the oropharyngeal region by fungus and supraglottic edema can lead to difficulties with mask ventilation and endotracheal intubation [8]. In one study, 3 patients had fungal debris in the oropharyngeal region, and in one of these patients, due to supraglottic edema, a video laryngoscope was used for endotracheal intubation [24]. In our study, mask ventilation was not difficult in any of our patients. First pass intubation success was 92.9%. Two attempts were made in 4 (7.0%) patients. Two patients required an intubation stylet for their endotracheal intubation and two patients had difficulty guiding the endotracheal tube through the glottis on the first attempt but the second attempt was successful. In one patient, mouth opening was present, therefore, fiberoptic bronchoscope-guided intubation was performed. Rest all patients are intubated by C-MAC video laryngoscope as per departmental COVID-19 protocol. We did not find any fungal debris in the oropharyngeal region and supraglottic edema in any of our patients. The intubation difficulty score was calculated with the help of the intubation difficulty scale. Eleven patients had no intubation difficulty, 42 patients had slight intubation difficulty (score 1–4), 3 patients had moderate to major intubation difficulty (score ≥5).

We had a dedicated COVID-19 operation theater with all the healthcare staff wearing level 3 personal protective equipment [25]. We checked all equipment and drugs for anticipated or unanticipated difficult airway management. We had masks of different sizes, stylets, bougies, laryngeal mask airways of different sizes, video laryngoscope (C-MAC) blades of different sizes, fiberoptic bronchoscope, 2 working suction apparatus, and an emergency tracheostomy trolley for management of the unexpected difficult airway.

COVID-19 is a major contributor to morbidity and mortality due to dyspnea, poor functional status, chest pain or tightness, hypercoagulability, endocrine abnormalities especially impaired glycemic control, etc. This, in addition to mucormycosis, makes the prognosis worse in these patients [26]. In our study 42 (73.7%) patients had a history of diabetes which was managed by administration of insulin perioperatively. Central venous catheters may be required perioperatively for blood or blood product transfusions, for fluid replacement, inotropic or vasopressor support, and long-term infusion of amphotericin B [27]. We used Groshong® PICC catheter (4 and 5 Fr) in 47 patients and internal jugular venous cannulation in 7 patients. The use of systemic amphotericin B in the management of mucormycosis associated with COVID-19 has its distinct toxicities, the most important being nephrotoxicity. There are other side effects of amphotericin B such as hypokalaemia, hypomagnesemia, fever, dyspnea, shivering, and hypotension [28]. In our study, 14 patients had preoperative amphotericin B-induced nephrotoxicity.
The primary objective of surgical management is to debride all necrotic tissues. Our patients received both antifungal treatment and surgical treatment. The overall mortality rate of mucormycosis reported in a study of 929 patients was 54%, with disseminated, gastrointestinal, pulmonary, rhinocerebral, and renal infections having the highest mortality rates. Mortality rates in sino-nasal and rhinocerebral mucormycosis have been reported to be 16 and 62 percent, respectively [11]. The mortality rate of mucormycosis associated with COVID-19 is still unknown. In our study, mortality occurred in 7 (12.3%) of 57 patients during their hospital stay. Five (12.2%) of 41 patients with sinonasal mucormycosis and 2 (14.3%) of 14 patients with rhino orbital mucormycosis (cerebral extension in 1 patient) expired.

Elevated \( \alpha \)-dimer levels has been associated with increased risk of severe disease and mortality in COVID-19 patients. [29] Some previous studies found increased levels of \( \alpha \)-dimer values in patients with COVID-19 associated mucormycosis [30,31]. In our study, we also found increased levels of pre-operative \( \alpha \)-dimer levels in our patients and that patients who died had statistically increased \( \alpha \)-dimer levels compared with discharged patients. Increased age is also considered a risk factor for mortality associated with COVID-19 associated mucormycosis [32]. We also found a statistically increased mortality in older patients.

We focused on airway difficulties related to mucormycosis related to COVID-19 in addition to procedural data and in-hospital mortality records. This is prime strength of our study as the literature on airway difficulty in patients with mucormycosis is sparse. Secondarily, there are only a fraction of studies showing records of mortality in patients with mucormycosis associated with COVID-19. Our article adds to existing literature related to this topic which can be instrumental in developing clinical guidelines and further study protocols.

Our study has some limitations. First, the study had a retrospective nature from a single center and was based on analysis of anesthesia and hospital records that may be subject to selection bias. Second, we used the video larynoscope as a first-line tool for endotracheal intubation in accordance with the COVID-19 recommendations. Difficulties may be greater if a direct larynscope has been used as an tool for endotracheal intubation. Third, in our study we did not report long-term follow-up of the discharged patients. At long-term follow-up, the mortality rate can be high. Fourth, the number of expired patients was comparatively small (7 patients) for statistical comparison with those who were discharged (50 patients).

### Conclusion

In patients undergoing surgery for mucormycosis associated with the coronavirus disease, airway management was easy to slightly difficult in most patients. Perioperative complications related to airways, the effect of COVID-19 and diabetes mellitus, systemic effects of amphotericin B can be reduced by taking timely and precautionary measures.

### Author’s contributions

- Prashant Sirohiya was involved in the conceptualization of the study, study design, patient care, data collection, statistical analysis, and in writing the first draft of the manuscript and agrees to be the guarantor of the manuscript taking responsibility for the integrity of the work as a whole, from inception to published article
- Saurabh Vig and Jitendra Meena were involved in the conceptualization of the study, study design, patient care, data collection, statistical analysis, and critique of the manuscript
- Tanmay Mathur, Girathra Goswami, and Raghav Gupta were involved in the conceptualization of the study, study design, patient care, and in writing the first draft of the manuscript
- Smriti Panda, Abhilash Konkimalla, and Dheeraj Kondamudi was involved in the conceptualization of the study, study design, patient care, and in the critique of the manuscript
- Nishkarsh Gupta, Brajesh Kumar Ratre, Ram Singh, Balbir Kumar, Anuja Pandit, were involved in study design, patient care, and in the critique of the manuscript
- Kapil Sikka and Alok Thakar were involved in the conceptualization of the study and final critique and review of the manuscript
- Sushma Bhatnagar was involved in the conceptualization of the study, convening of the working group, study design, patient care, in final critique and review of the manuscript and agrees to be the guarantor of the manuscript taking responsibility for the integrity of the work as a whole, from inception to published article

### Declaration of Competing Interest

The authors have no conflict of interest.

### Declarations: Ethics approval

The study was approved from Institutional Ethics Committee of All India Institute of Medical Sciences, New Delhi (IEC-450/02.07.2021)

### Availability of data and materials

Available on Request

### Funding

The authors received no funding for this project.

### Prior publication

The article has been hosted on the preprint server MedRxiv (https://doi.org/10.1101/2021.09.06.21263168)

### Support

Nil

### Permissions

Nil

### References

[1] Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020;26:944. e9-944.e15. doi:10.1016/j.cmi.2019.11.021.
[2] Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019;5:26. doi: 10.3390/jof5010026.
[3] Black fungus: india reports nearly 9,000 cases of rare infection. BBC News 2021.
[4] Elavarasi A, Sagiraju HRR, Garg RK, Ratte B, Sirohiya P, Gupta N, et al. Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: a cohort study. Lung India Off Organ Indian Chest Soc 2022;29:16–26. doi: 10.4103/lungindia.lungindia_493_21.
[5] Malhotra HS, Gupta P, Mehrotra D, Dandu H, Kohli N, Verma V, et al. COVID-19 associated mucormycosis: staging and management recommendations (Report of a multi-disciplinary expert committee). J Oral Biol Craniofacial Res 2021;11:569–80. doi: 10.1016/j.jobcr.2021.08.001.
[6] Sivia A, Pavleas I, Drogu Ariathirou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi 2020;6:265. doi: 10.3390/jof6040265.
[7] Anesthetic management of rhinoorbitocerebral mucormycosis: Focus on challenges – PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/3199350/(accessed July 21, 2021).
[8] Eckmann DM, Seligman L, Cote CJ, Hussong JW. Mucormycosis supraglottitis on induction of anesthesia in an immunocompromised host. Anesth Analg 1998;86:729–30. doi: 10.1097/00000539-199804000-00010.
[9] Malhotra N, Bajwa SS, Joshi M, Mehdiratta L, Kurdi M. Second wave of COVID-19 pandemic and the surge of mucormycosis: lessons learnt and future preparedness: indian society of anaesthesiologists (ISA National) advisory and position statement. Ind Anaesth 2021;65:427. doi: 10.4103/ija.ija_520_21.

[10] Laniado-Laborin R, MN Cabrales-Vargas. Amphoterionic B: side effects and toxicity. Rev Iberoam Micol 2009;26:223–7. doi: 10.1016/j.riam.2009.06.003.

[11] Mucormycosis Statistics | Mucormycosis | Fungal Diseases | CDC2020. https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html (accessed July 21, 2021).

[12] P. Sirohiya, S. Vig, T. Mathur et al. Journal of Medical Mycology 32 (2022) 101307

[13] Elavarasi A, Sagiraju HKR, Garg RK, Ratre B, Sirohiya P, Gupta N, et al. Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India-A cohort study. Infectious Diseases (except HIV/AIDS) 2021. doi:10.1101/2021.08.21.21261855.

[14] El-Ganzouri AR, McCarthy RJ, Tuman KJ, Tanck EN, Ivankovich AD. Preoperative airway assessment: predictive value of a multivariate risk index. Anesth Analg 2011;112:999–1007. doi: 10.1213/ane.0b013e3182369729.

[15] De Jong A, Pardo E, Rolle A, Bodin-Lario S, Pouzeratte Y, Jaber S. Airway management for COVID-19: a move towards universal videolaryngoscope? Lancet Respir Med 2020;8:555. doi: 10.1016/S2213-2600(20)30221-6.

[16] Mi Mouri, Krishnan S, Maani CV. Airway assessment. StatPearls, Treasure Island (FL): StatPearls Publishing; 2021.

[17] Scoppettuolo G, Biasucci DG, Pittiruti M. Vascular access in COVID-19 patients: smart decisions for maximal safety. J Vasc Access 2020;21:408–10. doi: 10.1177/1129729820923935.

[18] Karaa E. Anesthetic management of rhino-orbitocerebral mucormycosis: Focus on challenges. J Mycol Medecale 2019;29:219–22. doi: 10.1016/j.mycomed.2019.07.001.

[19] O’Loughlin EJ, Swann AD, English JD, Ramadas R. Accuracy, intra- and inter-rater reliability of three scoring systems for the glottic view at videolaryngoscopy. Anaesthesia 2017;72:835–9. doi: 10.1111/anae.13837.

[20] Doyle DJ, Goyal A, Bansal P, Garnon EH. American society of anesthesiologists classification. StatPearls, Treasure Island (FL): StatPearls Publishing; 2021.

[21] CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS | AIIMS Covid Information Portal n.d. https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/(accessed August 26, 2021).

[22] Mutthar T, Mathur T, Sirohiya P, Mehta S, Mathur T, Chhirya M, et al. Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India-A cohort study. Infectious Diseases (except HIV/AIDS) 2021. doi:10.1101/2021.08.21.21261855.

[23] Sheth RS, Shah DR, Shah RP, Shah K, Patel SB, Patel FS, et al. Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiol Rev 2020;28:295–302. doi: 10.1097/CRD.0000000000000330.

[24] Dravid A, Kashiva R, Khan Z, Bande B, Memon D, Kodre A, et al. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: a single centre experience from Pune, Western India. Mycoses 2022;65:326–40. doi: 10.1111/myc.13435.

[25] Goddanni N, Reddy YM, Kumar MK, Rajesh M, Reddy LS. Role of COVID 19 inflammatory markers in rhino-orbito-cerebral mucormycosis: a case study in predisposed patients at a designated nodal centre. Indian J Otolaryngol Head Neck Surg Off Publ Assoc Otolaryngol India 2021;1:7–10. doi:10.1007/s12070-021-02970-6.

[26] Patil A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multi-center epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerging Infect Dis J. - CDC 2021;Volume 27(Number 9) n.d. doi:10.3201/eid2709.210934.